Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 2/20 | 0.49 |
| ▸ | NOS3 | P29474 | 1/20 | 0.49 |
| ▸ | NOS1 | P29475 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | IKBKB | O14920 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL862162 | 0.83 | CYP1A2 (0.50) | CYP1A2S1PR2POLBKDM4EALDH1A1 | |
| SCHEMBL862340 | 0.82 | CYP1A2 (0.66) | CYP1A2S1PR2POLBKDM4EALDH1A1 | |
| SCHEMBL862383 | 0.81 | CYP1A2 (0.49) | CYP1A2S1PR2POLBKDM4EALDH1A1 | |
| SCHEMBL1178906 | 0.81 | NOS2 (0.54) | NOS2NOS3NOS1IKBKBTSHR | |
| SCHEMBL1178986 | 0.80 | MAPT (0.43) | CYP1A2POLBKDM4EALDH1A1KMT2A | |
| Hydrochloric Acid SCHEMBL1424993 | 0.80 | NOS2 (0.53) | NOS2NOS3NOS1ALDH1A1IKBKB | |
| SCHEMBL1178891 | 0.79 | NR1H2 (0.44) | CYP1A2POLBKDM4EALDH1A1KMT2A | |
| SCHEMBL862555 | 0.77 | CYP1A2 (0.44) | CYP1A2S1PR2POLBKDM4EALDH1A1 | |
| SCHEMBL22335927 | 0.77 | CYP1A2 (0.44) | NOS2CYP1A2S1PR2POLBKDM4E | |
| SCHEMBL1425236 | 0.76 | CYP1A2 (0.46) | CYP1A2POLBKDM4EALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102015695-B | Pyridin-2-yl derivatives as immunomodulating agents | ACTELION PHARMACEUTICALS LTD | 2014-08-27 | — | — | CN | disclosed |
| US-8598208-B2 | Pyridine derivatives as S1P1/EDG1 receptor modulators | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-12-03 | — | — | US | disclosed |
| US-8575200-B2 | Pyridin-2-yl derivatives as immunomodulating agents | ACTELION PHARMACEUTICALS LTD (CH) | 2013-11-05 | — | — | US | disclosed |
| EP-2252609-B1 | PYRIDIN-2-YL DERIVATIVES AS IMMUNOMODULATING AGENTS | ACTELION PHARMACEUTICALS LTD (CH) | 2013-04-17 | — | — | EP | disclosed |
| US-20110212998-A1 | PYRIDINE DERIVATIVES AS S1P1/EDG1 RECEPTOR MODULATORS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-01 | — | — | US | disclosed |
| CN-102015695-A | Pyridin-2-yl derivatives as immunomodulating agents | ACTELION PHARMACEUTICALS LTD | 2011-04-13 | — | — | CN | disclosed |
| EP-2195311-B1 | PYRIDINE DERIVATIVES AS S1P1/EDG1 RECEPTOR MODULATORS | ACTELION PHARMACEUTICALS LTD (CH) | 2011-03-23 | — | — | EP | disclosed |
| US-20110046170-A1 | NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-02-24 | — | — | US | disclosed |
| CN-101965346-A | Novel pyrimidine-pyridine derivatives | ACTELION PHARMACEUTICALS LTD | 2011-02-02 | — | — | CN | disclosed |
| US-20100331372-A1 | PYRIDIN-2-YL DERIVATIVES AS IMMUNOMODULATING AGENTS | VIATRIS ASIA PACIFIC PTE. LTD. (SG) | 2010-12-30 | — | — | US | disclosed |
| EP-2262800-A1 | NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2010-12-22 | — | — | EP | disclosed |
| EP-2252609-A1 | PYRIDIN-2-YL DERIVATIVES AS IMMUNOMODULATING AGENTS | Actelion Pharmaceuticals Ltd. (CH) | 2010-11-24 | — | — | EP | disclosed |
| EP-2195311-A1 | PYRIDINE DERIVATIVES AS S1P1/EDG1 RECEPTOR MODULATORS | Actelion Pharmaceuticals Ltd. (CH) | 2010-06-16 | — | — | EP | disclosed |
| WO-2009109872-A1 | PYRIDIN-2-YL DERIVATIVES AS IMMUNOMODULATING AGENTS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-09-11 | — | — | WO | disclosed |
| WO-2009109907-A1 | NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2009-09-11 | — | — | WO | disclosed |
| WO-2009024905-A1 | PYRIDINE DERIVATIVES AS S1P1/EDG1 RECEPTOR MODULATORS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331372-A1 | PYRIDIN-2-YL DERIVATIVES AS IMMUNOMODULATING AGENTS | IL2, FCGRT, CD4 | NOS2 447/4885NOS3 850/4885NOS1 876/4885 |
| US-20110046170-A1 | NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES | TYMP, DPYD, ENTPD5 | NOS2 2381/4885NOS3 2507/4885NOS1 2770/4885 |
| US-20110212998-A1 | PYRIDINE DERIVATIVES AS S1P1/EDG1 RECEPTOR MODULATORS | S1PR1, S1PR3, S1PR2 | NOS2 2411/4885NOS3 2145/4885NOS1 1194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.